Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma
The prognosis of high-risk neuroblastoma is poor despite the availability of multimodal treatment. Here the authors show that high-risk neuroblastoma is sensitive to indisulam, a selective degrader of the splicing factor RBM39 through the dual targeting of RNA splicing and metabolism.
Main Authors: | Anke Nijhuis, Arti Sikka, Orli Yogev, Lili Herendi, Cristina Balcells, Yurui Ma, Evon Poon, Clare Eckold, Gabriel N. Valbuena, Yuewei Xu, Yusong Liu, Barbara Martins da Costa, Michael Gruet, Chiharu Wickremesinghe, Adrian Benito, Holger Kramer, Alex Montoya, David Carling, Elizabeth J. Want, Yann Jamin, Louis Chesler, Hector C. Keun |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-03-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-022-28907-3 |
Similar Items
-
Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma
by: Yuewei Xu, et al.
Published: (2023-10-01) -
Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity.
by: Ziva Pogacar, et al.
Published: (2022-01-01) -
Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma
by: S. L. George, et al.
Published: (2020-05-01) -
Indisulam synergizes with melphalan to inhibit Multiple Myeloma malignancy via targeting TOP2A.
by: Chengyu Wu, et al.
Published: (2024-01-01) -
Indisulam synergizes with melphalan to inhibit Multiple Myeloma malignancy via targeting TOP2A
by: Chengyu Wu, et al.
Published: (2024-01-01)